eisai.com

Keyword	CPC	PCC	Volume	Score	Length of keyword
eisai.com	0.62	0.7	5537	9	9

Keyword	CPC	PCC	Volume	Score
eisai.com	0.09	1	138	83

Search Results related to eisai.com on Search Engine

A research-based pharmaceutical company | Eisai US
eisai.com

https://us.eisai.com/

WEBApr 12, 2024 · Learn the latest on Eisai's research, innovations, collaborations, events and more. Eisai is a research-based human health care company that discovers, develops and markets phamaceutical products internationally. Learn more about Eisai today.

DA: 99 PA: 6 MOZ Rank: 76

Eisai Co., Ltd.｜A human health care company
eisai.com

https://www.eisai.com/index.html

WEBMar 28, 2024 · Eisai Inc.'s U.S. Headquarters Earns Three Key Building Certifications Efforts Aimed to Help Sustain the Environment, Boost Employee Health & Wellness. March 9, 2023. Warning Against Solicitation, Fraudulent Emails, etc. that Use the Name of Eisai or Related Parties. February 17, 2023. EISAI SUPPORTS RELIEF EFFORTS FOR …

DA: 4 PA: 61 MOZ Rank: 77

Who we are as a medical solutions company | Eisai US
eisai.com

https://us.eisai.com/who-we-are

WEBEisai came to America in 1987 with one goal in mind: Create innovative new medicines to help patients, their families and caregivers. We’ve been breaking through ever since, with solutions and therapies that help improve the lives of the people we serve.

DA: 54 PA: 37 MOZ Rank: 85

Pharmaceutical oncology and neurology products | Eisai US
eisai.com

https://us.eisai.com/our-medicines/our-products

WEBWe work tirelessly to discover and develop products that give patients and their families the strength to keep fighting. Learn more about our solutions today.

DA: 13 PA: 19 MOZ Rank: 28

Eisai at a Glance | About Eisai | Eisai Co., Ltd.
eisai.com

https://www.eisai.com/company/glance/index.html

WEBA Leading Global Research and Development-Based Pharmaceutical Company Headquartered in Japan. Established in 1941, Eisai is a pharmaceutical company operating globally in terms of R&D, manufacturing and marketing, with a strong focus on prescription medicines. Over 80 years of history.

DA: 82 PA: 49 MOZ Rank: 37

Eisai Group Worldwide | Corporate Information | Eisai Co., Ltd.
eisai.com

https://www.eisai.com/company/profile/group/index.html

WEBEisai Co., Ltd. (Head Office) 4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan. Tel: 81-3-3817-3700. https://www.eisai.com/. EA Pharma Co., Ltd. 2-1-1 Irifune, Chuo-ku, Tokyo 104-0042, Japan. Tel: 81-3-6280-9500 Fax: 81-3-6280-9923. Pharmaceutical R&D / production / sales. https://www.eapharma.co.jp/en/.

DA: 3 PA: 70 MOZ Rank: 90

News Release：2024 | Eisai Co., Ltd.
eisai.com

https://www.eisai.com/news/index.html

WEBMar 22, 2024 · Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease to the U.S. FDA. March 29, 2024. EISAI TO DIVEST RIGHTS FOR MERISLON® AND MYONAL® IN JAPAN TO KAKEN PHARMACEUTICAL. March 28, …

DA: 47 PA: 24 MOZ Rank: 85

Corporate Information | About Eisai | Eisai Co., Ltd.
eisai.com

https://www.eisai.com/company/profile/index.html

WEBEisai Co., Ltd. Date Established: December 6, 1941 History; Head Office: 4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan Google Maps; Vicinity map for Headquarters; Japan Business Sites; Telephone: 81-3-3817-3700: Representatives: Haruo Naito, Representative Corporate Officer and CEO Yasushi Okada, Representative …

DA: 19 PA: 97 MOZ Rank: 41

Products | Business Activities | Eisai Co., Ltd.
eisai.com

https://www.eisai.com/company/business/products/index.html

WEBMajor Products. Sales Regions. Global Brands. Halaven (anticancer agent) Lenvima (anticancer agent) Fycompa (antiepileptic agent) Dayvigo (insomnia treatment) Japan, Americas, Europe, China, Asia. Japan, Americas, Europe, China, Asia.

DA: 32 PA: 100 MOZ Rank: 100

FDA Approves LEQEMBI™ (lecanemab-irmb) Under the ... - Eisai …
eisai.com

https://media-us.eisai.com/2023-01-06-FDA-Approves-LEQEMBI-TM-lecanemab-irmb-Under-the-Accelerated-Approval-Pathway-for-the-Treatment-of-Alzheimers-Disease

WEBJan 6, 2023 · Eisai announced the U.S. pricing and rationale for LEQEMBI today. Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. * Protofibrils are large Aβ aggregated soluble species of 75 …

DA: 3 PA: 94 MOZ Rank: 64